Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ritu Chadda
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
Idaho State University,
Medanta The Medicity,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Medanta The Medicity
ORCID:
0009-0006-3613-6841
Observed ORCID:
0009-0006-3613-6841
OpenAlex ID:
A5118749442
Sex Differences in Rats in the Development of and Recovery From Ethanol Dependence Assessed by Changes in Seizure Susceptibility
2001
·
Leslie L. Devaud
, Ritu Chadda
·
Alcoholism Clinical and Experimental Research
·
89
Sex Differences in the Central Nervous System Actions of Ethanol
2003
·
Leslie L. Devaud
, SPaul Alele
, et al.
·
Critical Reviews in Neurobiology
·
78
Sex differences in effects of mild chronic stress on seizure risk and GABAA receptors in rats
2004
·
Ritu Chadda
, Leslie L Devaud
·
Pharmacology Biochemistry and Behavior
·
48
Differential effects of mild repeated restraint stress on behaviors and GABAA receptors in male and female rats
2005
·
Ritu Chadda
, Leslie L. Devaud
·
Pharmacology Biochemistry and Behavior
·
39
Single Exposure to a Serotonin 1A Receptor Agonist, (+)8-Hydroxy-2-(di-n-propylamino)-tetralin, Produces a Prolonged Heterologous Desensitization of Serotonin 2A Receptors in Neuroendocrine Neurons in Vivo
2006
·
Gonzalo A. Carrasco
, Louis D. Van de Kar
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
20
FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
·
Clinical Cancer Research
·
12
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
·
Clinical Cancer Research
·
7
Fluoxetine-Induced Acquired Platelet Aggregation Defect: a Rare Cause of Oral Bleeding
2020
·
Neha Rastogi
, Goutomi Chatterjee
, et al.
·
Pediatric Hematology and Oncology
·
2
Supplementary Figure S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Data from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
Supplementary Table S7 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Figure S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Figure S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Figure S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025
·
Cara A. Rabik
, Shu Wang
, et al.
PDF
Supplementary Table S1 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Supplementary Table S3 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Show more works
View as search
Works count:
26
Citation count:
295
H-index:
7
I10-index:
6
Year
Topic
Type